Transplant Research Institute, James D. Eason Transplant Institute, Department of Surgery, College of Medicine, The University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Int J Mol Sci. 2022 Oct 5;23(19):11805. doi: 10.3390/ijms231911805.
Non-alcoholic fatty liver disease is a huge cause of chronic liver failure around the world. This condition has become more prevalent as rates of metabolic syndrome, type 2 diabetes, and obesity have also escalated. The unfortunate outcome for many people is liver cirrhosis that warrants transplantation or being unable to receive a transplant since many livers are discarded due to high levels of steatosis. Over the past several years, however, a great deal of work has gone into understanding the pathophysiology of this disease as well as possible treatment options. This review summarizes various defatting strategies including in vitro use of pharmacologic agents, machine perfusion of extracted livers, and genomic approaches targeting specific proteins. The goal of the field is to reduce the number of necessary transplants and expand the pool of organs available for use.
非酒精性脂肪性肝病是全球慢性肝衰竭的一个主要病因。随着代谢综合征、2 型糖尿病和肥胖症发病率的上升，这种疾病变得更为普遍。许多人的不幸后果是肝硬化，这需要进行移植，或者由于脂肪变性水平高而无法接受移植，因为许多肝脏被丢弃。然而，在过去几年中，人们在理解这种疾病的病理生理学以及可能的治疗选择方面做了大量工作。这篇综述总结了各种脱脂策略，包括体外使用药物制剂、提取肝脏的机器灌注以及针对特定蛋白质的基因组方法。该领域的目标是减少所需移植的数量，并扩大可用于移植的器官库。
